We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Concert Pharmaceuticals Inc | NASDAQ:CNCE | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 8.37 | 8.78 | 8.00 | 0 | 01:00:00 |
From Jul 2022 to Jul 2024
By Colin Kellaher
India's Sun Pharmaceutical Industries Ltd. on Thursday said it agreed to buy Concert Pharmaceuticals Inc. for an initial $576 million in cash.
Mumbai-based drugmaker Sun would pay an initial $8 a share for Concert, a 16% premium to Wednesday's closing price of $6.90 for the Lexington, Mass., late-stage biotechnology company.
Concert shareholders will also receive non-tradeable contingent value rights worth up to an additional $3.50 a share based on milestones tied to the company's deuruxolitinib drug candidate for alopecia areata, a chronic autoimmune skin disease that causes hair loss on the scalp, face or body.
Sun said it expects to complete the acquisition in the first quarter.
Trading in shares of Concert was halted premarket on Thursday.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 19, 2023 08:32 ET (13:32 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Concert Pharmaceuticals Chart |
1 Month Concert Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
